HOME         WEBSITE         SUBSCRIBE           E-GREETINGS   
                               

Friday, December 19, 2014

Government adds 175 more drugs and formulations to the Drug Control in last six months

Asserts that prices of life saving drugs have been reduced 

The Minister Chemicals and Fertilisers, Ananth Kumar has stated that within six months of the present Government coming to power 175 more drugs and formulations have been added to the Drug Control and their prices were reduced. Replying to a debate on the Calling Attention Motion in Lok Sabha today, he said, it is unprecedented that on 26 May 2014, the number of formulations and drugs were 440 and today the total number of drugs under the Drug Price Control is 617. He said the entire credit for this initiative goes to the Prime Minister's concern for the people of India. 

He said out of these drugs whose prices have gone down 47 drugs are for cancer, 22 drugs are for Diabetes; 19 drugs are for AIDS and 84 drugs are for cardio-vascular category for which price control has been added. The Minister asserted that that there are no drugs whose price can be said to have increased, leave alone prices skyrocketing. 

The Minister informed the House that according to new initiatives in the Ministry, every pharmaceutical company has to file Form 5 every quarter according to The Integrated Pharmaceutical Database Management System. More than 600 companies are already filing these forms. Through these forms his Ministry will be monitoring their quantity, quality, price and all the parameters. One more mechanism the Government of India is conceptualizing and thinking of implementing is setting up of a Price Monitoring Resource Unit in each State. This will be a very progressive step in the direction of price control, he added. 

Ananth Kumar asserted that the Government of India is not at all intervening in the National Pharmaceutical Pricing Authority. That is an independent authority. There is the DPCO 2013 under which it works. All the powers of Government of pricing according to Essential Commodities Act have been delegated to it. The Authority has brought in price control for 108 formulations on 10 June. 

He said that the price control continues, and there is no reversal. Because of that continuance of price control, pharmaceutical companies have gone to the court and there is no stay order also on the reduced prices. 
Posted by

Blog Archive

____________________________________________________________________________________________

Disclaimer - All investments in Mutual Funds and securities are subject to market risks and uncertainty of dividend distributions and the NAV of schemes may go up or down depending upon factors and forces affecting securities markets generally. The past performance of the schemes is not necessarily indicative of the future performance and may not necessarily provide a basis for comparison with other investments. Investors are advised to go through the respective offer documents before making any investment decisions. Prospective client(s) are advised to go through all comparable products in offer before taking any investment decisions. Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the fund will be achieved. Information gathered & material used in this document is believed to be from reliable sources. Decisions based on the information provided on this newsletter/document are for your own account and risk.


In the preparation of the material contained in this document, Varun Vaid has used information that is publicly available, including information developed in-house. Some of the material used in the document may have been obtained from members/persons other than the Varun Vaid and which may have been made available to Varun Vaid. Information gathered & material used in this document is believed to be from reliable sources. Varun Vaid however does not warrant the accuracy, reasonableness and/or completeness of any information. For data reference to any third party in this material no such party will assume any liability for the same. Varun Vaid does not in any way through this material solicit any offer for purchase, sale or any financial transaction/commodities/products of any financial instrument dealt in this material. All recipients of this material should before dealing and or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice.


Varun Vaid, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner. The recipient alone shall be fully responsible/are liable for any decision taken on the basis of this material. All recipients of this material should before dealing and/or transacting in any of the products referred to in this material make their own investigation, seek appropriate professional advice. The investments discussed in this material may not be suitable for all investors. Any person subscribing to or investigating in any product/financial instruments should do soon the basis of and after verifying the terms attached to such product/financial instrument. Financial products and instruments are subject to market risks and yields may fluctuate depending on various factors affecting capital/debt markets. Please note that past performance of the financial products and instruments does not necessarily indicate the future prospects and performance there of. Such past performance may or may not be sustained in future. Varun Vaid, including persons involved in the preparation or issuance of this material may; (a) from time to time, have long or short positions in, and buy or sell the securities mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation in the financial instruments/products/commodities discussed here in or act as advisor or lender / borrower in respect of such securities/financial instruments/products/commodities or have other potential conflict of interest with respect to any recommendation and related information and opinions. The said person may have acted upon and/or in a manner contradictory with the information contained here. No part of this material may be duplicated in whole or in part in any form and or redistributed without the prior written consent of Varun Vaid. This material is strictly confidential to the recipient and should not be reproduced or disseminated to anyone else.


Varun Vaid also does not take any responsibility for the contents of the advertisements published. Readers are advised to verify the contents on their own before acting there upon.


Published Credits goes to following sources & all the mentioned sources as footer below the published material- Bloomberg, Valueresearch Online, Capital Market, Navindia, Franklin Templeton, Kitco, SBI AMC, LIC AMC, JM Financial AMC, HDFC AMC, The Hindu, Business Line, Personal FN, Economic Times, Reuters, Outlook Money, Business Standard, Times of India etc.